Black Diamond Therapeutics Inc
NASDAQ:BDTX
Income Statement
Earnings Waterfall
Black Diamond Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-86.5m
USD
|
Operating Income
|
-86.5m
USD
|
Other Expenses
|
4m
USD
|
Net Income
|
-82.4m
USD
|
Income Statement
Black Diamond Therapeutics Inc
Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | ||||||||||||||||||||
Operating Expenses |
(16)
|
(22)
|
(29)
|
(38)
|
(46)
|
(57)
|
(70)
|
(87)
|
(107)
|
(124)
|
(127)
|
(122)
|
(110)
|
(97)
|
(93)
|
(89)
|
(86)
|
(87)
|
(86)
|
|
Selling, General & Administrative |
(4)
|
(5)
|
(8)
|
(12)
|
(16)
|
(19)
|
(21)
|
(24)
|
(27)
|
(29)
|
(30)
|
(30)
|
(29)
|
(28)
|
(28)
|
(27)
|
(27)
|
(29)
|
(27)
|
|
Research & Development |
(13)
|
(17)
|
(22)
|
(26)
|
(31)
|
(38)
|
(48)
|
(64)
|
(80)
|
(95)
|
(97)
|
(92)
|
(81)
|
(70)
|
(64)
|
(61)
|
(58)
|
(59)
|
(59)
|
|
Operating Income |
(16)
N/A
|
(22)
-36%
|
(29)
-33%
|
(38)
-31%
|
(46)
-21%
|
(57)
-22%
|
(70)
-23%
|
(87)
-26%
|
(107)
-23%
|
(124)
-16%
|
(127)
-2%
|
(122)
+4%
|
(110)
+9%
|
(97)
+12%
|
(93)
+4%
|
(89)
+4%
|
(86)
+4%
|
(87)
-2%
|
(86)
+1%
|
|
Pre-Tax Income | ||||||||||||||||||||
Interest Income Expense |
(5)
|
(6)
|
(6)
|
(5)
|
1
|
3
|
4
|
4
|
5
|
4
|
3
|
3
|
2
|
2
|
(0)
|
0
|
0
|
0
|
2
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
|
Total Other Income |
(0)
|
(0)
|
0
|
0
|
(0)
|
(1)
|
(2)
|
(2)
|
(3)
|
(3)
|
(2)
|
(2)
|
(1)
|
(1)
|
(0)
|
2
|
3
|
3
|
2
|
|
Pre-Tax Income |
(22)
N/A
|
(28)
-32%
|
(35)
-24%
|
(44)
-24%
|
(46)
-5%
|
(55)
-19%
|
(67)
-23%
|
(85)
-27%
|
(105)
-23%
|
(122)
-16%
|
(126)
-3%
|
(121)
+4%
|
(109)
+9%
|
(96)
+12%
|
(91)
+5%
|
(87)
+5%
|
(83)
+4%
|
(84)
-2%
|
(82)
+2%
|
|
Net Income | ||||||||||||||||||||
Income from Continuing Operations |
(22)
|
(28)
|
(35)
|
(44)
|
(46)
|
(55)
|
(67)
|
(85)
|
(105)
|
(122)
|
(126)
|
(121)
|
(109)
|
(96)
|
(91)
|
(87)
|
(83)
|
(84)
|
(82)
|
|
Net Income (Common) |
(22)
N/A
|
(28)
-32%
|
(35)
-24%
|
(44)
-24%
|
(46)
-5%
|
(55)
-19%
|
(67)
-23%
|
(85)
-27%
|
(105)
-23%
|
(122)
-16%
|
(126)
-3%
|
(121)
+4%
|
(109)
+9%
|
(96)
+12%
|
(91)
+5%
|
(87)
+5%
|
(83)
+4%
|
(84)
-2%
|
(82)
+2%
|
|
EPS (Diluted) |
-0.66
N/A
|
-0.87
-32%
|
-1.08
-24%
|
-1.33
-23%
|
-1.27
+5%
|
-1.51
-19%
|
-2.04
-35%
|
-2.38
-17%
|
-2.92
-23%
|
-3.39
-16%
|
-3.47
-2%
|
-3.33
+4%
|
-3.01
+10%
|
-2.64
+12%
|
-2.51
+5%
|
-2.38
+5%
|
-2.27
+5%
|
-1.65
+27%
|
-1.88
-14%
|